Gut-Modulating Agents and Amyotrophic Lateral Sclerosis: Current Evidence and Future Perspectives
Nutrients · 21.02.2024 · 16 (5) · 590
DOI: 10.3390/nu16050590 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Nutrients, online erschienen am 21.02.2024. Verfasst von Ahmed Noor Eddin und 4 weiteren Autor:innen. Beteiligte Einrichtung: College of Medicine, Alfaisal University, Riyadh 11533, Saudi Arabia. Hauptthemen laut MEDLINE: Amyotrophic Lateral Sclerosis, Gastrointestinal Microbiome, Microbiota. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 97 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Amyotrophic Lateral Sclerosis (ALS) is a highly fatal neurodegenerative disorder characterized by the progressive wasting and paralysis of voluntary muscle. Despite extensive research, the etiology of ALS remains elusive, and effective treatment options are limited. However, recent evidence implicates gut dysbiosis and gut–brain axis (GBA) dysfunction in ALS pathogenesis. Alterations to the composition and diversity of microbial communities within the gut flora have been consistently observed in ALS patients. These changes are often correlated with disease progression and patient outcome, suggesting that GBA modulation may have therapeutic potential. Indeed, targeting the gut microbiota has been shown to be neuroprotective in several animal models, alleviating motor symptoms and mitigating disease progression. However, the translation of these findings to human patients is challenging due to the complexity of ALS pathology and the varying diversity of gut microbiota. This review comprehensively summarizes the current literature on ALS-related gut dysbiosis, focusing on the implications of GBA dysfunction. It delineates three main mechanisms by which dysbiosis contributes to ALS pathology: compromised intestinal barrier integrity, metabolic dysfunction, and immune dysregulation. It also examines preclinical evidence on the therapeutic potential of gut-microbiota-modulating agents (categorized as prebiotics, probiotics, and postbiotics) in ALS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- College of Medicine, Alfaisal University, Riyadh 11533, Saudi Arabia.
ORCID-Profile: Ahmed Noor Eddin, Khaled Alkattan, Ahmed Yaqinuddin
Zitieren
APA
Noor Eddin, A., Alfuwais, M., Noor Eddin, R., Alkattan, K., & Yaqinuddin, A. (2024). Gut-Modulating Agents and Amyotrophic Lateral Sclerosis: Current Evidence and Future Perspectives. Nutrients, 16(5), 590. https://doi.org/10.3390/nu16050590
Vancouver
Noor Eddin A, Alfuwais M, Noor Eddin R, Alkattan K, Yaqinuddin A. Gut-Modulating Agents and Amyotrophic Lateral Sclerosis: Current Evidence and Future Perspectives. Nutrients. 2024;16(5):590. doi:10.3390/nu16050590
BibTeX
@article{NoorEddin2024,
author = {Noor Eddin, Ahmed and Alfuwais, Mohammed and Noor Eddin, Reena and Alkattan, Khaled and Yaqinuddin, Ahmed},
title = {Gut-Modulating Agents and Amyotrophic Lateral Sclerosis: Current Evidence and Future Perspectives},
journal = {Nutrients},
year = {2024},
volume = {16},
number = {5},
pages = {590},
doi = {10.3390/nu16050590}
}
EUVIMED